Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
COVID-19 and exosomes look similar under the microscope. Dr Andrew Kaufman thinks the COVID-19 positives might only be exosomes. Most people won't believe this but what has believing DR. Fauci and Birx, the NIH and CDC gotten us? House arrest for everybody!
https://mindanaogoldstardaily.com/the-science-behind-covid-19/
"WHAT is fearfully thought to be Covid-19 is just a harmless and beneficial enzyme naturally produced in the body to fight toxin: the exosome.
This is the professional conclusion reached by Dr. Andrew Kaufman, M.D., an American qualified physician who aired his professional view through a video uploaded on Youtube. His video shatters and debunks the myth propagated by Chinese medical authorities and sensationalized media about a novel virus called Covid-19."
We should not forget then everything the new crew has done. Like sell the IP for 8 million and 15% royalty, give away the exosome IP. If you think that it was a good deal to sell the IP to Oncologie, fine. It was a good deal for Oncologie. For 8 million they got Bavitaximab into two phase two advanced cancer trials with Mercks. Who wouldn't want that, 8 million for those two trials. Plus a third study for gliobastoma trial. Is Oncologie fronting any R&D like old PPHM did for $400 millions? It sure doesn't look so. And we obviously must love the transparency of it all.
Nobody knows yet what may come out of the exosomes science.
Not sure if that means that there will be more options doled out to the BOD and "high value" employees. Didn't they get their options already? Are they to get more? This stock only moves with the market on the way down but not on the way up. Nice.
And another thing: Just how long is going to take to hire a CEO? What are we supposed to think? There are no qualified candidates or they cannot find a candidate that is willing to follow their marching orders?
Unfortunately, I have to agree with you. Always hiding what they are doing and what's really going on. Like you said, they are running the company like a private company and not a public company, just like the old crew.
How did AVID get all those awards and two champion awards sixteen days after they went public with the equipment/processing problems and the need for repair? It doesn't add up to me.
I was afraid it would come to this when you consider who picked this team: the old crew and Ronin. It looks like they were picked to give the IP away for almost nothing and to sell AVID cheap. It looks like they are still working for those two no good entities.
Maybe not, but do you really believe like some others on this board that Bavi wasn't never worth anything, never worked, never had any promise. And that we got a great deal when it was sold off for eight millions along with the rest of the IP assets. (betabodies, exosomes which went back to some university).
Did anybody tell that to the investors who pumped in 80 millions for bavi to the buyer Oncologie, who somehow appeared in the middle of the night, and was fooled into paying 8 millions for bavi? Did anybody tell that to Mercks who is conducting combination trials with it? What a waste of time and resources!
Bavi should have been buried after the sabotage in phase II but somehow stumbled into a phase III trial? And is still being used in trials.
At this point, do we really want more institutional ownership? What has the increasing institutional ownership brought us other than a lower pps? If we have another or current institutional buyer wanting more shares it will do so by naming his price with the MMs who will oblige by driving the pps down to loose as many shares as they can from retail or small fish. This can be also be done in combination with shorting by either the new buyer or MMs. Can we afford this game to go on again? What is ironic is that a new institutional buyer will lower the pps for the older institutional buyers who did it to us when they bought and now they are having done to them. Isn't that funny?
Now, of course we are told that NASDAQ and the SEC are watching out for us and public companies. How often does supply and demand change the pps up or down as opposed to manipulation by the big fish? Isn't something fishy going on here and so many other stocks?
Also, what's relevant is that the first $500 million of future profits will be tax free. That means,the corporate tax rate being at 21%, CDMO will earn the full $500 million instead of $395 million. Has the new and better BOD ever mentioned that? Or did they give away the R&D expenses to Oncologie ( it sounds like such a boutique name) for nothing or for peanuts like they did with the IP.
I hope you are right but I doubt it. They didn't need to remove the poison pill if it's going to be a friendly take over. There isn't going to be any bidding for Bavi because it was sold to Oncologie. Maybe the potential royalties and profits from manufacturing Bavi can be included in the price of the take over deal. But it's too early for that. And the new BOD has said absolutely nothing about that so far. It looks like Bavi is being kept swept under the rug.
I am afraid whoever has been accumulating all these shares will get a low ball offer through the BOD and then they will have to votes to approve the deal with all the shares they have been accumulating.
Somebody on this board kept saying the purchase price was going to be $5. Maybe we will get a little more than that. I need $11 pps to break even but I will not really break even when I look at how much my investment here would be worth if I bought a mutual fund and sat on it for all these years.
The fact that they removed the poison pill strongly indicates that they will do a deal that is friendly to the BOD members only and will leave retail very disappointed. The BOD can get many or some very good benefits from the acquirer. Ask John Stafford how it is done.It looks like all of the accumulation through tactics like naked shorting and huge blocks of shares exchanging hands after the close indicates that BOD is going along with this and that is why they removed the poison pill.
I failed at my attempt at being sarcastic just like I failed at all of my attempts to make money in this stock. The :) at the end of my post means that I was joking and being sarcastic. Vinmantoo said that it is a fact that Bavi has failed in all of its clinical trials. Well, how could Bavi have made it to Phase III if it hadn't passed the pre-clinical, Phase I, and Phase II trials? When I said that Bavi failed a trial and was moved to the next trial I obviously meant that that was not possible.
CDMO owns Bavi, a drug that binds PS and has failed in all its clinical trials as an anti-oncology agent. You can talk all you like about PS targeting or about receptors that use PS as part of their mechanism, but it won't change the fa. ct that Bavi has failed in all its clinical trials
When they announce the first milestone payment it will come as a complete surprise on the upside and that should drive the pps even higher. Unless they are not going to announce it. Well, with everything that has been going on with PPHM/Avid even that falls under the realm of possibility.
First of all,
it's Oncologie not Oncology. You should know since it sounds like a french word.
How long does it take to buy 5000 shares? Last week I bought a total of 6400 on three different days (2400, 2000, 2000) and each time they got filled at the ask price in one second. The pps went higher each time after my purchase and then came down hard and now back up.
If 17% is not a bad deal, how much better is the deal Oncologie got when it bought the IP? What had Oncologie done before that to buy the IP at such a great price? Nothing!
You didn't become less active you just stopped posting.
Worst case scenario that is unfortunately likely. It all depends on whether John has the votes to get a breadcrumb sale through. Anybody have any idea if he does have enough votes?
Johny is a dirty active investor. He apparently doesn't want his buyer to pay anything near its value for the IP and even CDMO. Wall Street is very dirty for allowing such games to be played by truly bad characters. Nasdaq and the SEC are so far removed from their mission. John is trying to get the votes for the low buyout. Is there any hope that he won't be able to?
That's the best scenario for us. But we have an active investor by the name of John who who shown that he has other ideas and the last thing that he wants is to see retail prevail. If there is a low buyout will Johnny and company have enough votes to approve it? It seems less likely now with the large institutional investors and there might not be enough votes this time for their nefarious deeds. But one can never be too sure. Liar Lias is a puppet as most likely the rest of the BOD and Johnny and maybe still the old BOD are the masters.
We hope not to turn out bagholders.
McComb was picked by Ronin or the old BOD. Either way he could not possible be a good character. He could only be as bad as whoever nominated him to the board.That explains why the company is being run in the same manner as it was run under the old BOD. Has the new BOD proved that it is better than the new one? Has Lias proved that he is better than King?
Where do you see Roger and the new BOD picked by the old BOD and Ronin caring for the shareholders any more than the old regime?
How do you think the conversations of the new BOD candidates went with the old BOD and Ronin? Ronin told us there was so much low hanging fruit contracts ready to be picked. Well have they? Once they got they BOD guys in place Ronin stopped taking phone calls.
Someone might say but look at the facilities development. Well, have they done more than the old BOD in getting contracts? Give the old regime credit for building up the facilities to the point where the new regime would have a very easy time getting contracts if we are to believe Johns word.
as well as low to mid-single digit royalties on net sales upon commercialization of products utilizing r84.
It would have been better if the royalties were on gross sales. An accounting trick can really reduce or wipe out net sales. If they get creative enough they can do it over and over again so that we get little or no royalties.
Yes, look at this.
https://edition.cnn.com/2018/12/05/health/10-minute-cancer-test-intl/index.html
The 10-minute test developed in Australia is yet to be used on humans, and large clinical trials are needed before it can be used on prospective patients. But the signs are positive.
Tests on more than 200 tissue and blood samples detected cancerous cells with 90% accuracy, the researchers said.
It's been used only to detect breast, prostate, bowel and lymphoma cancers, but they're confident the results can be replicated with other types of the disease. Exsosomes what could have been.
Breast cancer: Know the facts 01:19
"Researchers have long been looking for a commonality among cancers to develop a diagnostic tool that could apply across all types," wrote Trau and his research partners, Sina and Laura Carrascosa, in an article for academic news site The Conversation.
Cancer alters the DNA of healthy cells, particularly in the distribution of molecules known as methyl groups, and the test detects this altered patterning when placed in a solution such as water.
"Using ... a high-resolution microscope, we saw that cancerous DNA fragments folded into three-dimensional structures in water. These were different to what we saw with normal tissue DNA in the water," the article explains.
The test uses gold particles, which bind with cancer-affected DNA and "can affect molecular behavior in a way that causes visible color changes," it added.
Carrascosa says that if proved, their method for detecting cancer could be a boon to providing detection and diagnosis in rural or underdeveloped areas. The technology for reading electrochemical signals is readily available, she says, and paired with a smartphone could be adapted to screen DNA affected by cancer.
"The advantage of this method, it is so simple -- it's almost equipment-free. You can do it with very low resources.
"There's another possibility that it can be used to monitor for relapses. We haven't tested that yet, but it is a potential."
The next step for the team is to stage clinical studies into how early cancer can be detected,and whether the test can be used to gauge the effectiveness of treatment.
They're also looking into the possibility of using different bodily fluids to detect different cancer types from early to the later stages of the disease.
Paid Content
This Cheap Drone Is Now The Best Selling Christmas Gift In Philippines
simplediscountfinder.com
Clay Trader review
He got 2.8 out of 5 stars.
From https://tradingskeptic.com/ about 60% of the page down.
ClayTrader Review – Is Clay For Real?
by The Trading Skeptic | May 22, 2018 | Reviews | 0 comments
ClayTrader Review – Is Clay For Real?
ClayTrader Review
Quality of Education
Price
Credibility of Educator
2.8
ClayTrader is a day trader who sells educational courses on technical analysis, level 2, options, forex, and other trading topics. ClayTrader markets himself as a normal guy that doesn’t drive a Ferrari or live in a mansion. The frontpage of his website says “I’m not a hot-shot Wall Street trader, but thanks to the stock market, I’ve gained the ultimate wealth: being my own boss. Let me help you achieve your freedom.” While I commend his honesty, there is something to be said about his position from a marketing standpoint. He pitches himself as the “anti-guru” while pitching the same products as the gurus he reviles.
Clay sells 14 training courses, and an “inner circle” subscription product which includes chat room and newsletter access. His most expensive course is $397, and you can get all of his courses for $1,997, which is significant, considering the average trading guru charges that for one course.
In this article to discuss ClayTrader, his services, products, and Clay the person.
Who is ClayTrader?
On ClayTrader’s about page, one can get a better idea of who Clay is as a person. He’s a 33 year old family man who quit his job at Honeywell through stock trading. He pays additional lip-service to his “anti-guru” persona, which probably plays really well with traders who are sick of seeing gurus flaunt their sports cars and women. One red flag I found, however, is the fact that he doesn’t disclose his real name. I understand his desire to keep his personal life private, as he does have a family, but, most people are uncomfortable giving a man hundreds of dollars without knowing his name.
Track Record
When the topic of trading gurus comes up, the discussion shortly arrive at their track record. What’s Clay’s annualized rate of return? What’s his lifetime gross trading profits? What did he clear in 2017 pre tax? Well, ClayTrader doesn’t disclose any of that information.
One should always keep in mind that in the regulated financial services space, disclosure isn’t a choice. Among the first questions one usually asks a potential financial advisor is about their track record. Should you treat your online trading gurus with the same rigor? That is up to you.
Chat Room
claytrader-chatroom
One can get access to ClayTrader’s “Inner Circle,” which gives you chat room access, for $99 per year. Relative to his industry, Clay’s prices are quite cheap, as $99 will only get you 1-2 months of chat room access from most other trading gurus.
I spent a few weeks watching Clay’s chat room while trading and watching the markets. After spending time in a multitude of chat rooms, I’ve developed somewhat of a critical lense towards them, some are atrocious, while others are amazing, supportive, and worth your time/money.
Clay’s chat room is full of friendly daily regulars who exchange trade ideas and alerts day-in-and-day-out. It was especially exciting to see that members of the room were actually contributing, and not just asking questions or giving useless information. In order to fully appreciate the chat room, you must be familiar with Clay’s trading “lingo,” which requires you to purchase his courses or go through tons of his YouTube tutorials. You’ll see technical levels, catalysts, and potential setups all called out in the chatroom. If you get one actionable trading idea per year from this chat room, it’s paid for itself.
Courses
claytrader-courses
Clay’s training courses are his bread and butter. He has 14 of them, and I’d venture say that they account for the majority of his business’ revenue. Of all of his courses, Robotic Trading seems to be his most popular course. The broad theme of Clay’s courses is removing the emotion from your trading and becoming one with the charts. The subject matter of each course is a subset of technical analysis. Whether that’s breakout trading, short selling, or mastering level 2, everything has to do with technical analysis.
In his Robotic course series, and throughout all of his courses, Clay emphasizes the importance of “being a robot,” or not allowing human error, emotions, or bias enter into your analysis. In his view, one would ideally program their brains to trade a certain way and allow that code to run on autopilot.
Personally, I have gone through his Robotic Trading Skill Sharpening, Risk Vs Reward Trading, Trampoline Trading, Shorting for Profit, Volcano Trading, Robotic Trading, and Mastering Level 2 courses. Of all of them, I have only found Mastering Level 2 and Shorting for Profit to be of significant value, because these topics have much less freely available information on them.
In Mastering Level 2, Clay effectively explains the market microstructure aspect of understanding level 2, as well as the psychology and goals of each market participant, and how this shows up on level 2. He goes into how to spot market maker activity and profit from it, how to spot the large institutions hiding their size, and how to spot naive retail traders (who are usually late and can be a contrarian indicator).
In Shorting for Profit, while not offering any proprietary material, Clay spends hours talking about short selling, the psychology of it, and various short setups. He takes the liberty to name common short setups like “Ruthless Short,” “Disgruntled Short,” “Dream Crusher Short,” “Dead Cat Bounce,” and “Broken Window Short.” The reason for this course having practical value is that short selling is not that popular in the trading community, and much less in-depth information is available on it. I’ve definitely made my money back from my purchase of Shorting for Profit, as I’ve successfully traded the “Dead Cat Bounce” (name not his), countless times.
My gripe with ClayTrader’s training courses is that the material is all so basic. In the majority of cases, the material in his courses can be found on Investopedia or similar sites. While this can be said about many trading courses, this is especially true in Clay’s case. Other trading gurus use their trading experience to give first hand nuanced advice about these concepts, showing their past trades as case studies, explaining their psychology while in the trade, and pointing out their rationale for their entries/exits. Clay’s material, on the other hand, feels too clinical. He even shows himself looking through scanner results for case study examples, rather than pulling from his own trade history.
Final Thoughts
One should note that Clay doesn’t make any big claims about his trading returns, career, or lifestyle. Only that he quit his job through trading. I’m not sure I’ve ever seen him make any concrete statements about specific trades or activity. Because of this, it’s hard to be overly critical of his business model. He isn’t flaunting sports cars and models and selling a dream lifestyle. Further, his prices are actually quite fair, relative to the industry.
However, most of the content that he sells can be found for free in the form of Investopedia articles, Youtube videos, and clever Google searching. There are even fully fledged free courses out there, like Adam Grimes’ course, which goes much further in-depth, and clearly pulls from firsthand experience.
This isn’t to say that Clay isn’t good at explaining concepts or doesn’t go in-depth, just that’s it feels to clinical if you’re an experienced trader. New traders who want all the content wrapped up in one course will get their money’s worth, if the money is expendable. Traders living paycheck-to-paycheck with tiny brokerage accounts are better off spending the extra time to search for the information individually.
Pros
No hype
Clay is a great educator
Excellent community and chat room
Competitive pricing
Cons
Feels too clinical
His track record isn’t shown
Other free options are available
As it has transpired even Mem Sloan Ket people are in it for themselves and they tried to make money anyway they can whether is unethical, illegal or at the expense of others who are unaware of it all and will be paying a price for it.
This means just all of the people at Mem SLoan Ket, Merck and all the other BPs, people who run trials, hedge funds like Ronin, Dart, and the big investment companies like MS, ML, and the super ethical people who sit on the boards of public companies. All of them are in it for themselves instead of what their job duties say, all of them except the new people sitting on the board of AVID, the new CEO Lias and everyone else he hired. That is what some believe. No matter that the new board and CEO were put in place by the old BOD and Ronin.
What if the owner of all those 7.50 calls is the seller of the same calls? How hard would it be to do that? If that is what happened all the buyers that drove the pps to above 9 were fooled by those who were selling while they were buying. Or maybe there are no head fakes in Wall Street it’s all on the up and up. Take your pick.
There is more than bottom line. You are saying that is OK to squander 400K plus on Lias because we squandered two million on the old BOD.Lias is not earning his obscene salary like the old BOD didn't earn theirs.John from Ronin talked about all of the long hanging fruit ready to be picked by AVID. Where is it? Enough time has passed.
Besides, Lias sounded like King on the last conference call and said in the ASM that nobody was interested in the IP only to find out that it is being used in a new phase II trial with additional trials being planned by Oncologie and their partner(s).Was that a lie? This is straight out of oncologie.com. You should visit it sometime.
And what did we get for a phase II drug? Eight million. Phase II drugs fetch billions. I know about the milestone payments and the royalties but how much of that will you get when and if AVID is swallowed by a bigger fish? Does nothing sounds like a good answer?
And since nobody was interested in the IP according to Lias how does it end up being bought by a private and new company and then end up in a phase II trial with more to come? Somebody must have said let's create a new company and buy Bavi beacuase it's not worth anything.
Maybe Frankie should investigate if the 400k+ unearned and obscene salary that was awarded to Lias by Carlton and et al is.nt being split between the old BOD members after they leave Lias what he deserves to get paid. Which shouldn’t,t be that much since Lias has not picked up enough of the low hanging fruit that the big Ronin head honcho was salivating about when he was making his move to oust the old BOD.
Are you done thanking the CDMO leadership?
It loooks like you are following the Robert Lichello AIM system. I had his book and never read it. I found it again years later and it has a chart that shows how having some core shares and using the rest of your money to buy on dips and sell after a good run beats the pants out of buying and holding. It works best with stocks that behave like CDMO and will not work with stocks tha never look back or recover.
We need this to go a lot higher. Let’s hope it starts now.
On a positive note,
CDMO has a lot of low hanging fruits that have yet to fully ripen before they are picked.
That was a question. I started to buy this stock fifteen years ago and I was one of the ones who wanted PPHM to partner when it was still in phase II. We know what happened. The price I paid for my last buy is $9.10. I need this dog to go to 19 to break even.
A different path to the same shareholders' value destruction?
So if all or most of Bavi is developed in Spain do we got more than nothing out of it? Or could it be that this is dictated by Spain's law?
Why is there an exception for Spain?
What do you think they are doing to keep the pps from going over 5 other than shorting. To trade to influence the pps is against the rules punishable by nothing.
Will the retail shareholders still be in the game if and when the sell the company for peanuts to some entity behind the shadows like they did with the IP?
UTSW and PPHM were perfectly fine in letting PPHM spend 300+ millions in trials. Does that mean anything?
Many years ago the argument was that nobody outside of PPHM knew or was talking about PS. When PS was in the news the argument was that nobody was talking about Bavi.
When SUNRISE was halted because of abnormal control arm results the argument was that Bavi failed.
The latest argument is what you said that Bavi is worthless.
What will or is the next argument? Maybe that PPHM never owned the patents which were licensed to them. What will the argument be about the 300 plus millions spent to develop Bavi? Does AVID now get them to offset any future earnings? Oh, I get it that will happen after AVID is sold for peanuts.